NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: OSO BioPharmaceuticals Manufacturing, LLC

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

OSO BioPharmaceuticals to Sponsor Forum on Subcutaneous Biologic Drug Delivery Trends - The 2011 DCAT Week Biologics Forum will present regulatory and pharmaceutical industry leaders discussing current requirements, trends and best practices for subcutaneous biologic drug delivery systems
OSO BioPharmaceuticals to Sponsor Forum on Subcutaneous Biologic Drug Delivery Trends

 

NewswireTODAY - /newswire/ - Albuquerque, NM, United States, 2011/02/22 - The 2011 DCAT Week Biologics Forum will present regulatory and pharmaceutical industry leaders discussing current requirements, trends and best practices for subcutaneous biologic drug delivery systems.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

OSO BioPharmaceuticals Manufacturing, LLC, will sponsor the Biologics Forum taking place March 16 as part of DCAT Week.

OsoBio is a contract manufacturing organization focusing on biologic and pharmaceutical injectables. Headquartered in Albuquerque, N.M., OsoBio specializes in products that require complex handling, including highly potent compounds.

The 2011 DCAT Week Biologics Forum will present regulatory and pharmaceutical industry leaders discussing current requirements, trends and best practices for subcutaneous biologic drug delivery systems. Participants will learn about innovations in products, tools and practices, as well as practical applications with case studies.

“Methodologies for qualifying primary container and delivery devices remain somewhat vague, which is why discussing case studies and sharing best practices is useful within the pharmaceutical industry, ” said Stuart Rose, president and CEO of OsoBio. “OsoBio is pleased to sponsor an event that advances quality and safety knowledge in our industry, ultimately benefiting the patients we all seek to serve.”

DCAT Week – sponsored annually by the Drug, Chemical and Associated Technologies Association (DCAT) – is considered by many participating industry representatives to be one of the most important meetings of the year.

The Biologics Forum is scheduled to take place Wednesday, March 16, from 1:15 pm. to 4:30 pm. in the Empire Room at the Waldorf-Astoria Hotel in New York City. A networking reception will follow.

DCAT invites representatives from non-member companies with interests in biologics to attend this program and networking event for the DCAT member price of $99. For registration information, visit osobio.com/.

OsoBio surpasses quality-assurance expectations within our industry. Our employees are industry veterans who provide innovative solutions to our clients’ most difficult projects.

Contact: Milton Boyer, VP business development and sales, 706-694-2514

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: OSO BioPharmaceuticals Manufacturing, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


OSO BioPharmaceuticals to Sponsor Forum on Subcutaneous Biologic Drug Delivery Trends

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Karen Stinneford - Sinclair & Co. for OsoBio 
919-833-9102 kstinneford[.]sinclair-co.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any OSO BioPharmaceuticals Manufacturing, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From OSO BioPharmaceuticals Manufacturing, LLC / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

IQIRVO® Demonstrates Statistically Significant Improvement in ALP Normalization in Patients with PBC in Phase IIIb ELSPIRE Study
Dysport® is the First Botulinum Toxin to Achieve Positive Topline Phase III Results in Both Episodic and Chronic Migraine
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development
Ipsen to Acquire Memo Therapeutics AG - Adding First-in-class BK Polyomavirus Antibody, Expanding Rare Disease Portfolio
Ipsen to Acquire Kartos Therapeutics, Expanding Hemato-oncology Late-stage Pipeline
Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con
Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity
Ipsen Unveils Corabotase, A First-in-class Recombinant Neuroinhibitor, RNI™ At the SCALE Symposium
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with CartriQ® BioPure
Ojemda® Approved in The European Union as the First Targeted Therapy in Relapsed or Refractory Pediatric Low-grade Glioma
Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Locus FS Receives the 2026 North American Precision Fermentation Technology Innovation Leadership Recognition
Ipsen Showcases Transformative Potential of Early Immuno-oncology Pipeline At AACR
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow, Inc.





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)